Biologic Guidance And Oversight Develops More Specifics In Japan And Korea
This article was originally published in The Pink Sheet Daily
Executive Summary
The influx of biologic and biosimilar INDs is forcing Japan’s PMDA and Korea’s KFDA to reorganize their approval processes.
You may also be interested in...
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.